Crinetics Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Checking your notes…
(In thousands, except per share amounts)
| ASSETS | ||
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | $101,536 | $264,545 |
| Restricted cash | — | 500 |
| Investment securities, amortized cost of $924,317 at December 31, 2025 and $1,088,561 at December 31, 2024 | 926,353 | 1,089,524 |
| Trade accounts receivable, net | 592 | — |
| Inventory | 2,022 | — |
| Prepaid expenses and other current assets | 17,839 | 20,819 |
| Total current assets | 1,048,342 | 1,375,388 |
| Property and equipment, net | 14,296 | 12,068 |
| Operating lease right-of-use assets | 40,492 | 43,507 |
| Restricted cash, net of current portion | 800 | 800 |
| Prepaid expenses and other assets, net of current portion | 22,327 | 2,829 |
| TOTAL ASSETS | $1,126,257 | $1,434,592 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $41,770 | $21,469 |
| Accrued compensation and related expenses | 35,578 | 28,887 |
| Deferred revenue | 1,235 | 2,176 |
| Operating lease liabilities | 6,489 | 7,152 |
| Total current liabilities | 85,072 | 59,684 |
| Operating lease liabilities, non-current | 42,052 | 44,570 |
| Deferred revenue, non-current | 3,810 | 4,704 |
| Other non-current liabilities | 3,240 | 829 |
| TOTAL LIABILITIES | 134,174 | 109,787 |
| Commitments and contingencies (Note 7) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2025 or 2024 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 95,575 shares issued and outstanding at December 31, 2025; 92,926 shares issued and outstanding at December 31, 2024 | 2,407,757 | 2,275,952 |
| Accumulated other comprehensive income | 1,865 | 963 |
| Accumulated deficit | (1,417,427) | (952,110) |
| Stock held in trust | (112) | — |
| TOTAL STOCKHOLDERS’ EQUITY | 992,083 | 1,324,805 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $1,126,257 | $1,434,592 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.